Showing posts with label C R Bard. Show all posts
Showing posts with label C R Bard. Show all posts

Monday, April 28, 2014

The Motley Fool: Do Disappointing Earnings Create a Good Buying Opportunity?

By most standards, Covidien (NYSE: COV  ) has been a superior performer in the med-tech sector. That hasn't always shown up in the company's stock performance, however, as rebound stories like St. Jude Medical, Boston Scientific, and Bard have raced ahead. With Covidien announcing a noisy quarter with some apparent seasonal pressures on Friday, it looks as though Fools have an opportunity to add shares in a high-quality name at a pretty interesting valuation.

Continue here:
Do Disappointing Earnings Create a Good Buying Opportunity?

Friday, April 25, 2014

Seeking Alpha: Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard

For a company with relatively modest underlying growth trends, C.R.Bard (BCR) has generated a fair bit of enthusiasm on the Street for the enhanced growth prospects bought through M&A and the royalty stream from Gore. Among the acquired products, investors are particularly keen on the prospects for the Lutonix drug-coated balloon and management's comments on the earnings call only seemed to add more confusion to already noisy situation. Bard is not a particularly cheap stock at these levels and the company is going to need better organic growth and clear differentiation in drug-coated balloons to support further gains.

Read the full article here:
Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard